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Abstract The tumor stroma is comprised of extracellular
matrix, non-malignant cells, and the signaling molecules
they produce. It is an integral and vital component of pri-
mary tumors that together with the underlying genetic
defects in the tumor cells determines the growth character-
istics, morphology, and invasiveness of the tumor. In paral-
lel to continuing genetic changes in the tumor cells
themselves, the tumor stroma progressively evolves during
primary tumor development. Cancer cells that disseminate
from primary tumors are dependent on this stromal micro-
environment, and therefore the microenvironment they en-
counter at secondary sites determines their fate. For those
cells that survive at these sites, stromal progression can
serve to re-establish a supportive tumor stroma, fostering
the outgrowth of the cells as metastases. Formation of a
metastatic niche that supports the survival and growth of
disseminated tumor cells is a key feature of this stromal
progression. The endogenous organ microenvironment can
provide components of the metastatic niche. In addition,
microenvironmental changes in organs prior to receipt of
disseminated tumor cells can be induced by factors secreted
systemically by primary tumors, causing the formation of
pre-metastatic niches. Further maturation of metastatic
niches can be responsible for the re-activation of dormant
disseminated tumor cells many years after removal of the
primary tumor. The concept of the metastatic niche and
stromal progression has profound consequences for our
understanding of metastatic disease, and promises to open
up new strategies for the diagnosis, prognostic evaluation,
and therapy of cancer.
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1 Introduction
After invading out of the primary tumor and entering the
vasculature, tumor cells can in principle be transported
throughout the body. A key step in the formation of metas-
tases is the exit of these circulating tumor cells (CTCs) from
the circulatory system and their entry into secondary sites to
become disseminated tumor cells (DTCs). In addition to the
intrinsic properties of these cells, the microenvironment
local to DTCs is critical in determining their fate [1]. The
term metastatic niche [2] has been coined to describe the
microenvironmental conditions required for the survival and
outgrowth of DTCs at these secondary sites. Metastatic
niches can be derived from the foundation of particular
microenvironments found endogenously in organs where
metastases form. Their formation can also be remotely in-
duced at least in part by primary tumors before the arrival
and establishment of DTCs (termed pre-metastatic niches).
Further remodeling may be required once DTCs have be-
come established so that the development of a fully mature
metastatic niche ensues.
The development and evolution of metastatic niches
should be seen in the broader context of tumorigenesis and
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tumor progression as a whole, as suggested by the stromal
progression model of metastasis [3]. In this model, the
formation of primary tumors is dependent not only on
progressive genetic changes in cancer cells but also on the
progressive development of an inflammatory tumor stroma.
These two processes are mutually dependent on each other
in a continual co-evolution. The dependency of primary
tumor cells on their stroma means that when they dissemi-
nate, the absence of the requisite stroma at secondary sites
determines that most if not all of the cancer cells are unable
to survive or simply remain dormant, depending on the
microenvironment they encounter. The formation of meta-
static niches either pre-metastatically or after the settlement
of DTCs serves to re-establish the stromal environment that
DTCs require for growth as tumors, and can be coupled to
further genetic changes in the tumor cells themselves. Thus,
the evolution of metastatic niches recapitulates stromal pro-
gression in the primary tumor [3].
The concept of the metastatic niche and stromal progres-
sion extends Paget’s seed and soil hypothesis [4] through
focusing on the properties of the microenvironmental soil
needed for successful metastasis formation by the metastatic
seed. In recent years, much progress has been made in
understanding key components of the metastatic niche,
how such niches form and are regulated, and the effects
they exert on the tumor cells they interact with. In this
review, I survey what we currently know about the
form, regulation and function of metastatic niches, and
discuss some of the potential clinical implications of their
existence.
2 Key components of the niche
Although investigation of the metastatic niche is still a
relatively young research field, a number of central func-
tional elements have emerged. These include a perivascular
location, modification of the extracellular matrix (ECM) and
remodeling of the vasculature, recruitment of bone marrow-
derived cells (BMDCs), hypoxia, and the expression of a
variety of signaling molecules (Fig. 1). Other non-
transformed cells such as endothelial cells and fibroblasts
are also important players.
2.1 Modified ECM
Formation of the metastatic niche is associated with the
deposition of new ECM components as well as with the
remodeling of the ECM constituents. For example, the de-
position of fibronectin, tenascin-C, periostin, and versican
have all been implicated in metastatic niche formation [5–8].
Accumulation of fibronectin produced by fibroblasts and
fibroblast-like cells has been reported to determine at which
sites metastatic niches form [5], although at least some of
the deposited fibronectin is derived from the primary tumor
[9]. Recent studies suggest that this deposition results in
coordinated remodeling of the ECM, as periostin acts as a
bridge that binds to tenascin-C as well as to fibronectin and
collagen type I, thereby serving to promote incorporation of
tenascin-C into the ECM [10]. Conversely, reduced levels of
the ECM protein fibulin-5 have been reported to be required
for metastasis formation in the liver and lung, probably
because fibulin-5 suppresses expression of matrix metallo-
proteinase (MMP)-9 [11], a protease that remodels the ECM
during metastatic niche formation and promotes metastatic
outgrowth [5, 12]. MMP-2 also plays an important role in
organizing the ECM of the metastatic niche [9]. Another
class of enzymes, the lysyl oxidases (LOX) and LOX-like
proteins (LOXL), are additionally actively involved in ECM
remodeling during niche formation due to their ability to
cross-link collagen and elastin, and are upregulated in re-
sponse to hypoxia via HIF-1α [9, 13, 14]. LOX produced in
response to hypoxia by primary tumors localizes to sites of
fibronectin deposition [9]. In addition to changing the con-
stitution of the ECM and thereby providing substrates for
tumor cells and the cellular components of the metastatic
niche, an important consequence of ECM remodeling is to
increase matrix stiffness, which can profoundly affect the
properties of tumors cells [15]. For example, metastasis
formation is promoted by Caveolin1 expression on fibro-
blasts, which serves to remodel and stiffen the ECM micro-
environment [16].
2.2 Perivascular location and vascular remodeling
Recent long-term intravital video microscopy experiments
using the mouse cranial window model have revealed that,
once extravasated, tumor cells require a strict perivascular
location if they are to survive [17]. This was true regardless
of whether the cells remained as single dormant cells or
grew out as metastases after vessel cooption or the induction
Fig. 1 Diagram showing the relationship between CTCs, DTCs, and
the metastatic niche. The current concept of the metastatic niche and
important components within it are illustrated
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of angiogenesis. VEGF-A inhibition was observed to push
perivascular tumor cells into a state of dormancy [17].
Further work is required to determine whether a perivascular
location is strictly required in all secondary organs. Earlier
intravital studies in the lung suggested that B16 melanoma
cells are randomly distributed 4 days after intravenous in-
jection, but after 10 days are located around arterial and
venous vessels [18].
Recent evidence also points to vascular remodeling as an
important event during formation of the metastatic niche
[19]. Other studies indicate that angiopoietin 2 (Angpt2),
MMP-3, and MMP-10 combine synergistically to increase
vascular permeability in the lung and disrupt vascular integ-
rity [20]. Disruption of vascular integrity is connected
with morphological changes in the endothelial cells and
the associated basement membrane, as well as with
primary tumor-induced fibrin deposition in the lung
[20].
2.3 Cellular niche components
Several types of BMDC are important constituents of the
metastatic niche. Hematopoietic progenitor cells that ex-
press vascular endothelial growth factor receptor-1
(VEGFR-1) are mobilized and recruited early during meta-
static niche formation. These cells express α4β1 integrin
(VLA-4), a surface receptor for fibronectin, which mediates
their recruitment to fibronectin-rich microenvironments
where pre-metastatic niches form [5]. They contribute to
ECM remodeling through secretion of MMP-9 [5, 12]. They
also contribute to the niche vasculature, both directly [21],
and through the generation of a microenvironment that
recruits VEGFR2+ circulating endothelial progenitor cells
[5]. CD11b+ (Mac-1+) cells are also recruited to metastatic
niches [22]. LOX activity at these sites cross-links collagen
IV, providing a substrate to which the CD11b+ cells adhere
and remodel [9]. Production of MMP-2 by the CD11b+ cells
cleaves collagen IV, releasing chemoattractive collagen IV
peptides. Together, these events attract further CD11b+ and
c-Kit+ BMDC, and recruit metastatic cells [9].
Chronic inflammation is associated with metastasis for-
mation [23–26], and accordingly a variety of inflammatory
cells that drive primary tumor growth are important compo-
nents of the metastatic niche. In addition to CD11b+ mye-
loid cells, other examples include tumor-associated
macrophages (TAMs), CD4+ T-reg cells, and certain classes
of neutrophils [27]. Surprisingly little is known about the
recruitment of some of these types of immune cell to devel-
oping metastases and their contribution to the metastatic
niche. CD4+ T-reg cells accumulate in lymph node metas-
tases [28–31]. They are also recruited to and required
for lung metastases in experimental breast tumors [32,
33].
Fibroblasts play an important role in metastatic niches
[2]. They produce a variety of growth factors and cytokines
such as S100A4, TGFβ, and SDF1a [34]. As pointed out
above, they constitute an important source of fibronectin [5].
They also produce tenascin-C, which augments that pro-
duced by breast cancer cells in micrometastatic lesions [6].
The importance of this stromally derived tenascin-C is dem-
onstrated by absence of lung metastasis formation when
breast cancer cells are implanted into tenascin-C-deficient
mice [35]. Furthermore, periostin is produced by stromal
fibroblasts in response to TGFβ3 [7]. Pulmonary fibrocytes
contribute to matrix remodeling through expressing MMP-9
[36].
In addition to providing a blood supply for the metastatic
niche and contributing to a perivascular microenvironment,
endothelial cells also play other roles in the niche. They are
a source of the pro-inflammatory cytokines S100A8 and
S100A9 that recruit CD11b+ myeloid cells to the niche,
and secrete other factors that stimulate the migration of
tumor cells [22]. Consistently, PECAM-1 expression on
endothelial cells has been reported to stimulate outgrowth
of metastases in the lung through a paracrine mechanism
[37].
2.4 Hypoxia
Hypoxia in the primary tumor plays an important role in
inducing the expression of factors that initiate and reg-
ulate formation of metastatic niches, for example
VEGF-A, PlGF, and LOX [5, 9, 13, 14]. However, it
is also likely that hypoxia within metastatic niches may
play an important role in the metastasis-promoting func-
tion of the niches. Hypoxia promotes the formation of
an inflammatory milieu [38], which supports metastatic
outgrowth, and which is likely to an important end
point of metastatic niche formation. Moreover, hypoxic
microenvironments upregulate SDF1α, and also recruit
VEGFR1+ and CD11b+ BMDCs [39].
2.5 Signaling molecules
Growth factors, cytokines, chemokines, and other pro-
teins produced by cellular components of the metastatic
niche are pivotal in the formation of metastatic niches,
for the attraction of CTCs, and for the survival and
outgrowth of DTCs [5, 9, 22, 40]. Members of the
Serum Amyloid A (SAA) acute phase proteins whose
expression is regulated by pro-inflammatory members of
the S100 family such as S100A8 and S100A9 play a
central role in the formation of metastatic niches and
their function [27]. Monocyte and macrophage-specific
chemokines are also constituents of the signaling mole-
cules found in metastatic niches [22].
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3 Regulation of niche formation
Our understanding of the regulation of metastatic niche
formation is still fairly rudimentary. When DTCs arrive at
distant sites, the endogenous organ microenvironment may
provide some or possibly even all of the components of the
metastatic niche structures the DTCs require to survive and
grow. The hematopoietic stem cell niche in the bone has
been shown, for example, to provide prostate cancer cells
with the microenvironment they require for metastasis for-
mation [41, 42]. However, most studies suggest that remod-
eling of the microenvironment is required to produce a fully
competent metastatic niche, either before the arrival of tu-
mor cells and/or after the establishment of DTCs at second-
ary sites. Research to date has largely focused on primary
tumor-induced pre-metastatic remodeling in the lung. The
prevalence of endogenous niche structures in particular
organs, or organ-specific metastatic niche formation, may
underlie patterns of metastatic outgrowth [5]. For example,
it is conceivable that the preferential outgrowth of metasta-
ses in organs such as lymph nodes, lungs, liver, brain, and
bone is due to the presence of endogenous microenviron-
ments in these organs that already contain many metastatic
niche components, and can therefore be more readily
remodeled to produce metastatic niches. Alternatively or in
addition, such endogenous microenvironments may be pres-
ent at higher densities in metastasis-prone organs than in
other organs. Nevertheless, the inefficiency of metastasis
formation observed in experimental animals (e.g., [18])
probably suggests that even the most conducive endogenous
niche microenvironments are sparsely distributed in organs
where metastases develop.
Experimental animal models in which cultured cancer
cells are implanted in vivo and give rise to metastatic
primary tumors have been instrumental in defining how
primary tumors can prime future sites of metastasis
formation by establishing pre-metastatic niches. A key
finding that has emerged from these studies is that
factors derived from primary tumors can act in a variety
of ways to induce pre-metastatic niche formation. A
number of growth factors and cytokines produced by
tumors have been shown to have systemic effects that
result, for example, in the mobilization and recruitment
of BMDC, and ECM remodeling. VEGF-A and PlGF
produced by primary tumors mobilize and recruit
VEGFR1+ VLA-4+ BMDC to fibronectin-rich pre-
metastatic sites in the lung [5]. Factors produced by
the primary tumor such as VEGF-A, TNFα, and TGFβ
also induce expression of the pro-inflammatory cyto-
kines S100A8 and S100A9 in developing pre-
metastatic niches in the lung. In turn, S100A8 and
S100A9 induce expression of SAA proteins that then
recruit CD11b+ myeloid cells to these sites [22, 40].
Systemic levels of osteopontin produced by primary
tumors have also been shown to play a role in activating
BMDC [43]. Recent studies further implicate primary
tumor-derived coagulants in the recruitment of CD11b+
cells to pre-metastatic niches [44]. As yet undefined primary
tumor-derived factors upregulate expression of Angpt2,
MMP-3, and MMP-10 in the lung mesenchyme, resulting
in disruption of vascular integrity that is required for recruit-
ment of CD11b+ cells [20]. Pre-metastatic induction by
primary tumors of lymphangiogenesis in regional lymph
nodes is also induced by tumor-produced VEGF-A and
VEGF-C [45–47], and is associated with poor prognosis
[48]. Our own studies show that by inhibiting these pre-
metastatic changes, the outgrowth of metastases in the
lymph nodes is inhibited (Quagiata et al., manuscript sub-
mitted), providing further evidence of the importance of
vascular remodeling in the metastatic niche. Finally, micro-
vesicles and exosomes derived from primary tumors have
also been demonstrated to play a role in mediating pre-
metastatic changes in putative sites of metastasis formation,
for example by inducing expression of VEGF-A, MMP-2,
and MMP-9 at these sites [49–52].
The recruitment of BMDC to pre-metastatic sites induces
further remodeling of the microenvironment. CD11b+ my-
eloid cells contribute to modification of the ECM by depos-
iting versican in developing metastatic niches [8]. They
additionally secrete large amounts of MMP-9, which remod-
els the ECM and the vasculature [19, 22, 40]. The recruited
VEGFR1+ BMDCs also contribute to MMP-9 expression,
together with local endothelial cells [5]. Both VEGFR1+
and CD11b+ cells can incorporate into tumor endothelium
and contribute to vascular remodeling, angiogenesis, and
vasculogenesis [5, 53, 54]. Loss of systemically acting
primary tumor-produced angiogenesis inhibitors upon sur-
gical removal of the primary tumor can also stimulate the
outgrowth of metastases [55].
The power of the animal models used to study pre-
metastatic niche formation lies in the rapid tumor growth
and ease of experimental manipulation. However, they do
not faithfully mimic the growth and development of autoch-
thonous tumors that occur in human cancer patients. It
therefore remains to be demonstrated the degree to which
the development of pre-metastatic niches in human cancer
patients contributes to metastasis formation. There are, how-
ever, already some indirect indications that this might be the
case. For example, for many types of cancer, it is well
established that the size of the primary tumor correlates with
the probability of metastasis formation [56] (although this is
not invariably the case [57]). As we have seen above,
soluble factors produced by primary tumors have been iden-
tified as initiators of pre-metastatic niche formation. The
circulating levels of pre-metastatic niche-inducing factors
would be expected to rise as a function of tumor size
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because the larger the primary tumor, the more of these
factors would be expected to be produced. Accordingly,
the circulating levels of VEGF and PlGF, initiators of the
mobilization and recruitment of VEGFR1+ BMDC, can
correlate with tumor size [58–61]. Furthermore, the numbers
of circulating VEGFR1+ monocytic cells are reduced in
patients with recurrent glioblastoma treated with aflibercept,
a recombinant decoy receptor that sequesters VEGF and
PlGF [62]. Moreover, clusters of VEGFR1+ BMDCs are
observed in putative sites of metastasis formation in breast
cancer patients before tumor spread [5].
Pre-metastatic formation of niche structures does not
explain why metastases grow out many years after apparent
successful therapeutic eradication of the original primary
tumor. Viable DTCs can be found in cancer patients many
years after surgery without any signs of overt metastases
being present [63], and thus are thought to be in a state of
dormancy as a consequence of cell cycle arrest [64]. Tumor
cells also remain dormant as small clusters of cells known as
micrometastases in which there is a balance between prolif-
eration and apoptotic cell death [1]. Genetic changes in the
dormant cells, for example loss of metastasis suppressor
genes [65] or upregulation of VCAM-1 [66], can stimulate
the awakening of dormant tumor cells. However, as dis-
cussed below, the induction of metastatic niche formation
in the locality of dormant cells may also re-activate them
and support subsequent metastatic outgrowth [3]. Our un-
derstanding of the induction or maturation of metastatic
niches in this context is still at an elementary stage. Patho-
logical events such as chronic inflammation or extensive
tissue trauma could conceivably play an initiating role
through inducing sustained systemic levels of the growth
factors and cytokines that induce metastatic niche
formation.
The picture that emerges from the experimental evidence
to date is that starting from the endogenous organ microen-
vironment, a continual stromal evolution ultimately gives
rise to fully mature metastatic niches capable of supporting
metastatic outgrowth (Fig. 2). Some of this remodeling can
occur pre-metastatically in response to systemic primary
tumor-derived factors. Further remodeling can occur once
tumor cells occupy nascent metastatic niches. Formation or
maturation of metastatic niches can also take place many
years after seeding of DTCs. Thus, the development of
metastatic niches forms part of a mutually dependent co-
evolution of tumor cells and their microenvironment at
primary and secondary sites [3].
4 Functions of the metastatic niche
The overarching function of the metastatic niche is to
determine the fate of DTCs, namely whether they
survive, become dormant, or progressively grow to form
fulminant metastases. A number of mechanisms have
been uncovered that allow them to do this, as outlined
below. There are also indications that metastatic niches
can signal to and attract CTCs. Accordingly, the differ-
ent components of the metastatic niche combine to
mediate these different functions. Nevertheless, tumor
intrinsic properties are also required if tumor cells are
to interact productively with the metastatic niche. For
example, the metastasis suppressor gene KAI1/CD82
downregulates fibronectin expression and β1 integrin
activation in prostate cancer cells [67], thus inhibiting
the ability of tumor cells to interact with niche
components.
Fig. 2 Diagram illustrating our current understanding of stromal pro-
gression at sites of metastasis formation. Intrinsic properties of CTCs
determine their ability to extravasate into distant organs. In these
organs, CTCs encounter either the endogenous niche environment of
the organ concerned or a remodeled pre-metastatic niche microenvi-
ronment that has been induced by the primary tumor. This pre-
metastatic remodeling may be sufficient by itself to produce a meta-
static niche that is competent to support metastasis. Alternatively,
additional microenvironmental remodeling may be required once a
DTC has become established in situ to convert either the endogenous
organ microenvironment or a partially remodeled pre-metastatic niche
into to a fully competent outgrowth-supporting metastatic niche. A
number of factors are listed that may be required for the remodeling
that results in metastatic niche formation. Various fates are possible for
DTCs. These are determined by the intrinsic properties of the DTC as
well as by the particular microenvironment that the DTC finds itself in
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4.1 Attraction of CTCs and stimulation of extravasation
Several components of metastatic niches have been reported
to actively induce CTCs to home to the niche. SAA3 pro-
duced in response to S100A8 in pre-metastatic lung niches
not only recruits CD11b+ cells but also attracts and recruits
CTCs to these sites [40]. The VEGFR1+ BMDC and asso-
ciated fibroblasts produce SDF-1, which recruits CXCR4-
positive tumor cells to pre-metastatic niches [5]. Pre-
metastatic destabilization of the vasculature in the lung
serves to promote the extravasation of CTCs, thereby stim-
ulating the formation of lung metastases [20]. The ECM
constitution and conformation in the metastatic niche pro-
vides substrates with which integrins and other receptors on
the surface of tumor cells can interact (e.g., [5]).
4.2 Establishment of an inflammatory milieu
Arguably one of the most important functions of metastatic
niche formation is to foster the formation of an inflamma-
tory microenvironment that recapitulates the tumor–stroma
interactions that drive primary tumor growth, and thereby
supports metastatic outgrowth. A number of mechanisms in
the metastatic niche have been uncovered that act in this
way. The induction of S100A8/A9 expression in the pre-
metastatic niche that in turn induces expression of SAA
family members has emerged as an important inducer of
an inflammatory milieu [27]. The S100A8 induced in the
pre-metastatic lung in response to factors secreted by pri-
mary tumors promotes the expression and secretion of
SAA3. In turn, SAA3 recruits myeloid cells and also posi-
tively auto-regulates itself via the TLR-4 receptor [40].
TLR-4-expressing Clara cells in the terminal bronchioles
participate in this auto-amplification of SAA3 expression.
Thus, specific depletion of Clara cells inhibits both metas-
tasis formation and recruitment of CD11b+ cells [68]. SAA
proteins are also chemotactic for other inflammatory cells
such as mast cells and T lymphocytes [69, 70], induce the
expression of ECM remodeling enzymes [71, 72], and stim-
ulate production of inflammatory cytokines such as TNF-α
[68] that promote tumor growth [73, 74]. A number of
positively acting feed forward loops exist between TNF-α,
SAA, and S100A8/A9 expression, amplifying these inflam-
matory responses [27]. In addition, CD11b+ Gr-1+ cells
also contribute to the expression of pro-inflammatory cyto-
kines in the metastatic niche [19].
4.3 Survival signals
The metastatic niche provides a number of survival func-
tions for DTCs. Integrin-mediated interactions of DTCs
with the modified niche ECM induce focal adhesion kinase
(FAK) signaling, which promotes both proliferation and
survival [75]. The cross-linking of matrix components by
lysyl oxidases serves to increase FAK signaling [15]. Matrix
stiffness was found to promote chemoresistance in hepato-
cellular carcinoma cells [76]. Macrophages in the metastatic
niche provide survival signals for VCAM-1-expressing tu-
mor cells through direct intercellular interactions [77].
CD11b+ 1 Gr1+ cells are myeloid-derived suppressor cells
(MDSC) that inhibit T-cell and NK-cell-mediated immune
responses and induce T-cell tolerance in cancer [78–81],
thus protecting DTCs from destruction via the immune
system.
4.4 Stemness
An idea that has taken root in cancer biology in recent years
is that of the cancer stem cell (CSC). Similar to stem cells
that both self-renew and give rise to committed progenitors,
this hypothesis suggests that populations of tumor cells are
organized in a hierarchical manner, with a CSC subpopula-
tion giving rise to the bulk of tumor cells [82]. Importantly,
CSCs are operationally distinguished from other tumor cell
subpopulations by their ability to initiate the growth of
tumors in experimental animals, even as single cells [83].
In contrast, even high numbers of implanted non-CSCs are
incapable of establishing tumors. Accordingly, subpopula-
tions of tumor cells defined by expression of defined
markers and with tumor-initiating properties in vivo have
been ascribed stemness properties, including the ability to
seed spheroids and expression of genes associated with stem
cells [84]. From the point of view of metastasis, the defini-
tion of CSCs suggests that DTCs with stemness properties
should be the founding cells of secondary tumors [85].
Emerging data suggest that CSC identity is plastic, and that
stemness properties need to be maintained and can be ac-
quired by non-CSC populations [3]. Stem cells require a
niche to maintain their properties, and components of the
metastatic niche have been similarly shown to induce or
maintain properties associated with stemness in DTCs
[86]. Thus, the metastatic niche may promote the establish-
ment of metastases by endowing DTCs with stemness
properties.
The perivascular microenvironment in metastatic niches
can initiate and maintain CSC properties. If located in a
perivascular location, non-CSC subpopulations can acquire
stemness properties [87]. The perivascular niche induced in
response to VEGF-A maintains the stemness of skin tumor
CSCs [88]. A similar perivascular location maintains glioma
CSCs [89] and probably also the CSCs of other tumor types
[86].
Hypoxic niches maintain the undifferentiated state of a
variety of normal stem cells [90]. Correspondingly, in addi-
tion to inducing the formation of niches, hypoxia has been
reported to maintain the stemness properties of CSCs [91,
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92]. Thus, hypoxia in the metastatic niche would be
expected to support metastatic outgrowth by nurturing the
metastasis-initiating CSC population, although this remains
to be formally demonstrated.
The ECM is a potent regulator of stemness properties.
Integrin-mediated activation of FAK signaling in response
to ECM microenvironments that typify metastatic niches
can enforce CSC identify [93]. Periostin in metastatic niches
serves to concentrate and present Wnt ligands, and thereby
induces and maintains stem-like metastasis founder cells [7].
Similarly, tenascin-C supports the stemness properties of
metastasis founder cells by increasing their responsiveness
to Wnt and Notch [6]. Matrix stiffness has been associated
with the regulation of CSC properties [76]. Activity of the
transcriptional co-activator TAZ is regulated by matrix stiff-
ness [94], and this activity endows breast cancer cells with
stemness properties [95].
4.5 Epithelial–mesenchymal transition
Induction of the morphogenetic process of epithelial to
mesenchymal transition (EMT) continues to attract much
attention as a mechanism that promotes metastasis. During
EMT, tumor cells lose epithelial characteristics and acquire
mesenchymal properties typified by changes in cellular
morphology, altered cell–cell and cell–matrix adhesion,
and the development of migratory behavior and invasive-
ness [96, 97]. Although most studies have focused on the
role of EMT in primary tumor invasion, EMT is increasingly
being recognized as endowing tumor cells with a number of
other properties of relevance to metastasis formation, in-
cluding the generation and maintenance of CSCs
[98–100], escape from signals that induce apoptosis or
anoikis such as loss of substrate contact and attack from
the immune system [3, 101–103], and resistance against
many chemotherapeutic agents [100].
Constituents of the metastatic niche have been associated
with the induction of EMT. The remodeling of the ECM that
is typical of that found in metastatic niches contributes to
EMT [104]. For example, EMT is promoted by the meta-
static niche constituent periostin [7]. The lysyl oxidase-like
enzyme LOXL2 enhances the activity of the transcriptional
repressor Snail1 and thereby induces EMT [105]. MMPs
that are activated in the metastatic niche induce EMT [106].
Increased matrix stiffness modifies the response of tumor
cells to TGFβ by triggering EMT rather than apoptosis
[107]. EMT is strongly and reversibly induced by hypoxia
[108]. The presence of inflammatory cytokines in the meta-
static niche such as IL-1β can also evoke EMT [109, 110].
It has been proposed that metastases are seeded by CSCs
that undergo EMT, allowing then to invade away from the
primary tumor and to disseminate [111, 112]. To account for
similarities in phenotype between primary tumors and their
metastases, as well as the association of EMTwith cell cycle
arrest (see below), it has been further suggested that the
reverse process of mesenchymal to epithelial transition
(MET) occurs once they reach the secondary site [111,
112]. To date, there has been little direct experimental evi-
dence to support the induction of MET in DTCs. However, a
recent study has shown that the metastatic niche ECM
component versican can stimulate MET in tumor cells by
reducing phospho-Smad2 levels, resulting in enhanced pro-
liferation and faster metastasis formation [8]. Thus, it is
conceivable that the metastatic niche can both stimulate
and reverse EMT, possibly depending on its state of matu-
ration. Indeed, it has been suggested that interchangeable
EMT and MET partial transitions that are dynamically reg-
ulated by the microenvironment determine invasiveness,
tumor cell survival, dormancy, and CSC identity in both
primary tumors and in metastatic sites [3].
4.6 Dormancy
Niche structures can act to promote DTC survival, but
maintain them in a state of dormancy. For example, a
perivascular location is required for the survival of DTCs
entering the brain, even if they remain dormant [17]. Hyp-
oxia can also induce dormancy [113]. The induction of EMT
in DTCs within the niche may also render the cells prolif-
eratively dormant due to increased levels of p16ink4a [114],
repression of cyclin D expression [115, 116], and persistent
expression of Twist [117]. The presence of cytostatic CD8+
T cells can also induce dormancy [118]. Dormancy confers
resistance to cytotoxic chemotherapy on DTCs because their
cell cycle arrest or slow proliferative turnover renders DNA-
damaging agents that target cycling cells ineffective [119].
On the other hand, dormant DTCs eventually need to be
reactivated if they are to grow out as overt metastases. As
the metastatic niche matures, a number of niche components
can act to release DTCs from dormancy. Alterations in the
contingent of cytokines can relieve dormancy induced by
CD4+ T cells [120]. Remodeling of the ECM, for example
through deposition of collagen type I, has been implicated in
releasing tumor cells from dormancy, and acts by enhancing
integrin-mediated FAK signaling [121, 122]. The urokinase
receptor uPAR activates β1-containing integrins, allowing
them to interact with fibronectin, thereby releasing tumor
cells from dormancy [123]. Angiogenic dormancy is re-
lieved by the induction of angiogenesis, and the ability of
VEGF-A to suppress dormancy [17] partly reflects this.
5 Clinical implications
Although basic research into metastatic niches is still at a
relatively early stage, it is already clear that the formation
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and maturation of pre-metastatic and post-dissemination
metastatic niches has a number of important potential clin-
ical implications, both from the diagnostic and prognostic
perspective, as well as for the design of effective metastasis
therapy. By monitoring processes that foster the formation
of metastatic niches, it may be possible to identify new and
powerful biomarkers that allow metastatic progression to be
detected before overt metastasis form. Monitoring the levels
of growth factors and cytokines in the blood that induce
niche formation is one example. Furthermore, assessment of
the levels in the blood of cellular components of metastatic
niches such as circulating VEGFR1+ BMDC or CD11b+
myeloid cells may be informative. For the patient, the mon-
itoring of such biomarkers may allow early and more effec-
tive therapeutic intervention, before overt metastases are
even detected. In addition, these biomarkers may provide a
surrogate measure of metastasis formation, facilitating clin-
ical trials of novel therapeutics that target metastatic disease.
Inhibition of stromal progression in metastatic sites as
well as the disruption of metastatic niches are possible new
approaches to the treatment of metastatic disease. Targeting
key immune cells such as CD11b+ myeloid cells may be
one option. Interfering with the establishment of an inflam-
matory milieu through targeting the positive feed forward
loops that operate in metastatic niches would be another
approach. Once we understand better how dormant DTCs
become activated, further therapeutic strategies should be-
come apparent. Therapeutic release from dormancy is likely
to sensitize DTCs to chemotherapy. Alternatively, if ways
can be identified to therapeutically maintain DTC dormancy
indefinitely, cancer could be rendered a chronic rather than a
life-threatening disease.
Pre-clinical studies that have targeted pre-metastatic
changes in the liver have already proven effective in exper-
iment models. TSU68, a low molecular weight inhibitor of
VEGFR-2, PDGFRβ, and FGFR1, reduces CXCL1 expres-
sion that is increased pre-metastatically in the liver in re-
sponse to primary metastatic colon tumors, and suppresses
metastasis formation [124]. CXCR2 is the cognate receptor
for CXCL1. It is expressed on the colon tumor cells and is
functionally required for metastasis formation in this model.
TSU68 also reduces the amount of IL-12 in the portal vein
and decreases the number of migrating neutrophils in the
pre-metastatic liver. Together, these data suggest that TSU68
suppresses pre-metastatic niche formation by inhibiting in-
flammatory responses induced by the primary tumor [124].
6 Conclusions
The concept of the metastatic niche is still discussed con-
troversially, reflecting the still limited number of publica-
tions in this area to date, as well as uncertainties regarding,
for example, the relevance of DTCs to metastasis formation,
the role of BMDC in tumor angiogenesis, and the precise
definition of CD11b+ subsets. Nevertheless, this concept
and more broadly the notion of stromal progression has
turned attention from tumor-intrinsic mechanisms, such as
genetic changes that determine metastasis formation, to the
importance of microenvironmental regulation of metastasis.
Although considerable progress has been made in recent
years, there is still much more to learn and a number of
key open questions remain to be addressed. Some of the
most important of these concern the regulation of DTC
dormancy. What microenvironmental changes initiate re-
lease from dormancy and outgrowth of metastases, and what
external events trigger these microenvironmental changes?
To answer these questions, a fuller understanding of stromal
progression at secondary sites is required, and how the
evolution of metastatic niches is regulated. What are key
steps in this evolution, and how does the form and function
of the niche change as the niche matures? What defines
endogenous niches in different organs, and what constitu-
ents do they contribute to the mature niche? What deter-
mines where pre-metastatic niches form, and to what degree
is their formation relevant to human cancer? What are the
minimal requirements for a pre-metastatic niche, and how
do DTCs contribute to further maturation of the metastatic
niche once they occupy these niches? Answering these
questions will not only dramatically enlighten our under-
standing of the metastatic process but will also provide new
strategies for the effective treatment and management of
metastatic cancer.
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